High impact information on Heavy Chain Disease

• Gamma heavy chain disease: rapid, sustained response to cyclophosphamide and prednisone [1].
• Pre-B-cell development in the absence of lambda 5 in transgenic mice expressing a heavy-chain disease protein [2].
• For IF2, whose deletion is like that seen in some human heavy chain disease proteins, the most likely explanation is an error of recombination [3].
• Protein Riv is a human gamma 1 heavy chain disease immunoglobulin variant with a deletion of the entire VH and CH1 domains and consisting of most of the hinge region plus the CH2 and CH3 domains [4].
• These results suggest the existence of a common mechanism defect leading to deletions/insertions in alpha heavy chain disease rather than a specific interaction between alpha 1 IgH gene with a unique defined molecular species [5].

Chemical compound and disease context of Heavy Chain Disease

• In addition, this is the first report of fludarabine activity in Franklin's disease [6].
• Gamma heavy chain disease (gamma HCD) has been found in approximately 60 patients (Franklin 1978) since its discovery in 1964 (Franklin et al. 1964) [7].
• alpha chain disease, the most frequent of the heavy chain diseases, is a proliferative disorder of B lymphoid cells involving primarily the small intestine and mesenteric nodes [8].

Biological context of Heavy Chain Disease

• Alpha heavy chain disease of patient MAL: structure of the non-functional rearranged alpha gene translocated on chromosome 9 [9].

Anatomical context of Heavy Chain Disease

• A series of mouse myeloma cell lines producing mutant gamma 2b immunoglobin heavy chains, which resemble heavy chain disease proteins, were analyzed for messenger RNA abundance as a function of mRNA alterations [10].

Gene context of Heavy Chain Disease

• Human alpha heavy chain disease (HCD) is characterized by the presence in patient's serum of a short Ig alpha chain devoid of light chains [11].
• Gamma heavy chain disease and rheumatoid arthritis [12].
• The association of mu heavy-chain disease with either hyperglobulinemia or a positive DAT has not been reported in the literature to date [13].
• N-ras oncogene activation in a patient with gamma heavy chain disease [14].
• Detection and preparation of immunoglobulin (Ig) mu chain protein in sera of patients with heavy chain diseases (HCD) [15].

Analytical, diagnostic and therapeutic context of Heavy Chain Disease

• 8 sera from patients with three types (gamma, alpha, mu) of heavy chain disease were tested by two-dimensional immunoelectrophoresis (Td. IEP) in order to assess the potential usefulness of such a technique as a routine diagnositc tool for heavy chain disease [16].
• Immunoelectrophoresis, immunoelectrophoresis immunoselection, and rocket immunoselection techniques are used to demonstrate the presence of alpha heavy chain disease proteins in four patients' sera [17].

References